Korean J Obstet Gynecol.  1997 Jan;40(1):161-169.

Expression of c-erbB-2 and p53 Oncogene in Cervical Intraepithelial Neoplasia and Uterine Cervical Carcinoma

Abstract

Recently, the oncogene and tumor suppressor gene have been recognized as important factors that is contribute to conversion and progression from normal cell to cnacer one. In the current study, expression rates of c-erbB-2 and p53 oncoprotein were analysed in biopsy tissues of uterine cervix to learn whether the expression rates of p53 and c-erbB-2 were related with prognostic factors. The c-erbB-2 and p53 expression rates of group with invasive cervical carcinoma versus control group were 53.6% vs 17.7% and 51.4% vs 9.7%, respectively. There was stastically significant elevation of e-erbB-2 and p53 oncogene expression in patients with invasive cervical carcinoma(p < 0.01). In comparison of invasive cervical carcinoma with CIN, there were stastically significant differences in p53 expression rates(51.4% vs 28.9%) and c-erbB-2 expression rates(53.6% vs 20.2%) and co-expression rates(31.1% vs 6.8%)(p < 0.01). Also in CIN patients, CIN III group showed statistically significant elevation than CIN I and CIN II group(p < 0.01). Among histologic cell types, the expression rate of p53 was higher in sqamous cell carcinoma than in adenocarcinoma. Except for the expression rate of p53 according to histologic cell type, no statistical difference in expression rates of c-erbB-2 and p53 were found according to age, clinical stage, lymph node metastasis in invasive cervical carcinoma(p > 0.05). In conlcusion, c-erbB-2 and p53 oncoprotein are thought to be possible factors in the carcinogenesis of cervical carcinoma and correlate with progression of it. But continuous analysis and follow up of 5 year survival are desirable to determine the role as prognostic factor and correlation with prognostic factors.

Keyword

c-erbB-2; p53; Cervical intraepithelial neoplasia; Invasive cervical carcinoma
Full Text Links
  • KJOG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr